Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $93.3 million.

  • Entrada Therapeutics' Cash & Current Investments rose 19.52% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.8 million, marking a year-over-year decrease of 16.16%. This contributed to the annual value of $101.2 million for FY2024, which is 49.72% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Cash & Current Investments stood at $93.3 million, which was up 28.70% from $72.5 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Cash & Current Investments high stood at $263.9 million for Q1 2022, and its period low was $45.2 million during Q4 2022.
  • In the last 3 years, Entrada Therapeutics' Cash & Current Investments had a median value of $78.0 million in 2024 and averaged $99.4 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Cash & Current Investments plummeted by 75.93% in 2023, and later skyrocketed by 132.31% in 2024.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Cash & Current Investments stood at $45.2 million in 2022, then spiked by 49.70% to $67.6 million in 2023, then soared by 49.72% to $101.2 million in 2024, then climbed by 19.52% to $93.3 million in 2025.
  • Its Cash & Current Investments stands at $93.3 million for Q3 2025, versus $72.5 million for Q2 2025 and $67.8 million for Q1 2025.